| Revision as of 20:12, 19 December 2024 editBoghog (talk | contribs)Autopatrolled, Extended confirmed users, IP block exemptions, New page reviewers, Pending changes reviewers, Rollbackers, Template editors137,879 edits ce; templated cites← Previous edit |
Revision as of 22:10, 19 December 2024 edit undoWiiformii (talk | contribs)Extended confirmed users, Pending changes reviewers, Rollbackers31,615 editsm →top: Typo fixing, typo(s) fixed: 1980’s → 1980sTag: AWBNext edit → |
| Line 4: |
Line 4: |
|
| image = Mcn 5707.svg |
|
| image = Mcn 5707.svg |
|
| width = 250px |
|
| width = 250px |
|
| caption = |
|
| caption = |
|
|
|
|
|
<!-- Clinical data --> |
|
<!-- Clinical data --> |
| Line 22: |
Line 22: |
|
| class = |
|
| class = |
|
| ATC_prefix = |
|
| ATC_prefix = |
|
| ATC_suffix = |
|
| ATC_suffix = |
|
|
|
|
|
<!-- Legal status --> |
|
<!-- Legal status --> |
|
| legal_status = |
|
| legal_status = |
|
|
|
|
|
<!-- Pharmacokinetic data --> |
|
<!-- Pharmacokinetic data --> |
| Line 35: |
Line 35: |
|
| elimination_half-life = |
|
| elimination_half-life = |
|
| duration_of_action = |
|
| duration_of_action = |
|
| excretion = |
|
| excretion = |
|
|
|
|
|
<!-- Identifiers --> |
|
<!-- Identifiers --> |
| Line 59: |
Line 59: |
|
| StdInChIKey = KWMNBUDYCCTHHL-SJLPKXTDSA-N |
|
| StdInChIKey = KWMNBUDYCCTHHL-SJLPKXTDSA-N |
|
}} |
|
}} |
|
Mcn 5707 is a ] agent designated for the treatment of depression. It was developed by ] of ] (now Johnson & Johnson) in the 1980’s.<ref>{{cite journal | vauthors = Maryanoff BE, Shank RP, Gardocki JF | date = 1986 | title = McN-5707 and McN-5652-Z | journal = Drugs of the Future | volume = 11 | issue = 1 | pages = 18 | doi = 10.1358/dof.1986.011.01.51629 }}</ref><ref name="pmid6747993">{{cite journal | vauthors = Maryanoff BE, McComsey DF, Castanzo MJ, Setler PE, Gardocki JF, Shank RP, Schneider CR | title = Pyrroloisoquinoline antidepressants. Potent, enantioselective inhibition of tetrabenazine-induced ptosis and neuronal uptake of norepinephrine, dopamine, and serotonin | journal = Journal of Medicinal Chemistry | volume = 27 | issue = 8 | pages = 943–6 | date = August 1984 | pmid = 6747993 | doi = 10.1021/jm00374a001 }}</ref> |
|
Mcn 5707 is a ] agent designated for the treatment of depression. It was developed by ] of ] (now Johnson & Johnson) in the 1980s.<ref>{{cite journal | vauthors = Maryanoff BE, Shank RP, Gardocki JF | date = 1986 | title = McN-5707 and McN-5652-Z | journal = Drugs of the Future | volume = 11 | issue = 1 | pages = 18 | doi = 10.1358/dof.1986.011.01.51629 }}</ref><ref name="pmid6747993">{{cite journal | vauthors = Maryanoff BE, McComsey DF, Castanzo MJ, Setler PE, Gardocki JF, Shank RP, Schneider CR | title = Pyrroloisoquinoline antidepressants. Potent, enantioselective inhibition of tetrabenazine-induced ptosis and neuronal uptake of norepinephrine, dopamine, and serotonin | journal = Journal of Medicinal Chemistry | volume = 27 | issue = 8 | pages = 943–6 | date = August 1984 | pmid = 6747993 | doi = 10.1021/jm00374a001 }}</ref> |
|
|
|
|
|
|
|
|
For related agents, see ], ], ], ] & ]. |
|
For related agents, see ], ], ], ] & ]. |
